xylometazoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihistaminics or local vasoconstrictors, antazoline derivatives 3658 526-36-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • xylometazoline
  • rhinoxilin
  • otrivine
  • xylometazoline hydrochloride
  • xylometazoline HCl
nasal decongestant
  • Molecular weight: 244.38
  • Formula: C16H24N2
  • CLOGP: 5.38
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 24.39
  • ALOGS: -4.44
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.80 mg N

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Reversible cerebral vasoconstriction syndrome 141.94 27.76 26 961 2632 63485403
Thunderclap headache 101.86 27.76 14 973 217 63487818
Rebound nasal congestion 89.78 27.76 10 977 20 63488015
Subarachnoid haemorrhage 48.53 27.76 15 972 14268 63473767
Nasal mucosal disorder 41.10 27.76 7 980 462 63487573
Cerebral artery stenosis 40.94 27.76 7 980 473 63487562
Anticholinergic syndrome 40.52 27.76 9 978 2373 63485662
Nasal turbinate hypertrophy 37.70 27.76 7 980 756 63487279
Nasal septum deviation 32.81 27.76 7 980 1529 63486506
Allergy to animal 28.45 27.76 6 981 1240 63486795

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 280.89 74.56 74 2469 8527 34945861
Appendicitis 241.13 74.56 74 2469 14733 34939655
Blood phosphorus increased 240.45 74.56 64 2479 7657 34946731
Cardiogenic shock 202.25 74.56 75 2468 26543 34927845
Stress 196.24 74.56 76 2467 30271 34924117
Ventricular fibrillation 182.88 74.56 67 2476 22887 34931501
Ascites 180.70 74.56 81 2462 46490 34907898
Abdominal distension 151.28 74.56 77 2466 58415 34895973
Dry mouth 148.06 74.56 62 2481 30103 34924285
Multiple organ dysfunction syndrome 129.17 74.56 76 2467 76490 34877898
Hyponatraemia 126.33 74.56 77 2466 82614 34871774
General physical health deterioration 115.51 74.56 86 2457 128183 34826205
Blood uric acid increased 114.75 74.56 38 2505 9586 34944802
Myasthenia gravis 114.10 74.56 35 2508 6905 34947483
Constipation 87.19 74.56 75 2468 136907 34817481
Blood cholesterol increased 86.72 74.56 38 2505 20505 34933883
Sepsis 80.23 74.56 78 2465 166483 34787905
Abdominal pain 77.62 74.56 76 2467 163542 34790846
Somnolence 75.04 74.56 63 2480 111053 34843335

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 320.47 38.55 74 3320 8477 79732517
Blood phosphorus increased 255.70 38.55 64 3330 10283 79730711
Appendicitis 255.22 38.55 74 3320 20720 79720274
Cardiogenic shock 207.98 38.55 75 3319 41839 79699155
Ventricular fibrillation 196.17 38.55 67 3327 31859 79709135
Ascites 184.45 38.55 81 3313 75481 79665513
Stress 164.56 38.55 76 3318 79536 79661458
Abdominal distension 146.27 38.55 80 3314 119570 79621424
Reversible cerebral vasoconstriction syndrome 138.95 38.55 31 3363 3026 79737968
Multiple organ dysfunction syndrome 132.20 38.55 75 3319 120171 79620823
Blood uric acid increased 122.46 38.55 38 3356 13322 79727672
Dry mouth 121.93 38.55 64 3330 87955 79653039
Myasthenia gravis 118.59 38.55 35 3359 10364 79730630
Hyponatraemia 116.98 38.55 80 3314 177768 79563226
Sepsis 107.82 38.55 90 3304 269338 79471656
General physical health deterioration 91.99 38.55 83 3311 275155 79465839
Rebound nasal congestion 88.33 38.55 11 3383 20 79740974
Constipation 86.11 38.55 81 3313 282969 79458025
Thunderclap headache 79.84 38.55 14 3380 391 79740603
Analgesic therapy 67.09 38.55 14 3380 995 79739999
Drug therapy 64.66 38.55 14 3380 1187 79739807
Somnolence 64.32 38.55 64 3330 238917 79502077
Abdominal pain 61.50 38.55 79 3315 389490 79351504
Sleep disorder therapy 61.14 38.55 13 3381 1011 79739983
Hyperphosphataemia 57.82 38.55 18 3376 6358 79734636
Blood cholesterol increased 53.32 38.55 37 3357 83683 79657311
Incorrect route of product administration 52.87 38.55 27 3367 34902 79706092
Iron deficiency 52.48 38.55 19 3375 10635 79730359
Bacterial infection 43.94 38.55 23 3371 31257 79709737
Neuralgia 42.53 38.55 23 3371 33361 79707633
Vomiting 40.59 38.55 88 3306 665740 79075254

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R01AA07 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Sympathomimetics, plain
ATC R01AB06 RESPIRATORY SYSTEM
NASAL PREPARATIONS
DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
Sympathomimetics, combinations excl. corticosteroids
ATC S01GA03 SENSORY ORGANS
OPHTHALMOLOGICALS
DECONGESTANTS AND ANTIALLERGICS
Sympathomimetics used as decongestants
ATC S01GA53 SENSORY ORGANS
OPHTHALMOLOGICALS
DECONGESTANTS AND ANTIALLERGICS
Sympathomimetics used as decongestants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D014663 Nasal Decongestants
MeSH PA D019141 Respiratory System Agents
MeSH PA D014662 Vasoconstrictor Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Heart disease contraindication 56265001 DOID:114
Diabetes mellitus contraindication 73211009 DOID:9351
Transsphenoidal hypophysectomy contraindication 171948002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST Ki 5.98 PDSP SCIENTIFIC LITERATURE
Alpha-1A adrenergic receptor GPCR Ki 7.04 CHEMBL
5-hydroxytryptamine receptor 1B GPCR Ki 7.89 CHEMBL
5-hydroxytryptamine receptor 1D GPCR Ki 9.15 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 7.82 PDSP
Alpha-2C adrenergic receptor GPCR Ki 6.89 PDSP
Adrenergic receptor alpha-2 GPCR IC50 7.64 CHEMBL
Adrenergic receptor alpha-1 GPCR IC50 6.24 CHEMBL
Adrenergic receptor alpha GPCR Ki 8.32 CHEMBL

External reference:

IDSource
4020518 VUID
N0000148237 NUI
D00757 KEGG_DRUG
1218-35-5 SECONDARY_CAS_RN
4020500 VANDF
4020518 VANDF
C0078643 UMLSCUI
CHEBI:10082 CHEBI
CHEMBL312448 ChEMBL_ID
DB06694 DRUGBANK_ID
CHEMBL1256400 ChEMBL_ID
C009695 MESH_SUPPLEMENTAL_RECORD_UI
5709 PUBCHEM_CID
517 IUPHAR_LIGAND_ID
809 INN_ID
WPY40FTH8K UNII
226046 RXNORM
12647 MMSL
5697 MMSL
001804 NDDF
004727 NDDF
372841007 SNOMEDCT_US
75327003 SNOMEDCT_US
76289007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SinosilNasal Decongestant HUMAN OTC DRUG LABEL 1 44237-007 SPRAY 0.02 mL NASAL OTC monograph final 14 sections
Metarivin Soln. 0.1% HUMAN OTC DRUG LABEL 1 72988-0030 LIQUID 1 mg NASAL unapproved drug other 7 sections
Aqua Maris Fast Acting Decongestant HUMAN OTC DRUG LABEL 1 76260-106 SPRAY 10 mg NASAL OTC monograph final 13 sections
Aqua Maris Kids Fast Acting Decongestant HUMAN OTC DRUG LABEL 1 76260-107 SPRAY 0.05 mg NASAL OTC monograph final 12 sections